Cartiva raises $8.5M in Series D; ImThera starts sleep apnea study;

@FierceMedDev: ICYMI: Philips CEO outlines HealthTech vision as shareholders vote to separate lighting biz. Story | Follow @FierceMedDev

@VarunSaxena2: Concordia running trials to expand use of its laser-activated cancer-fighting drug. FierceDrugDelivery article | Follow @VarunSaxena2

@EmilyWFierce: Novartis grabs Zykadia approval in Europe, setting the stage for PD-L1 showdown. ICYMI from FiercePharma | Follow @EmilyWFierce

> San Diego's ImThera Medical announced that the first two patients were implanted with its investigational aura6000 System to treat sleep apnea. More

> A plethora of high-tech sensors and apps are being developed to track sleep patterns so that customers can feel well-rested. More

> Cartiva has raised $8.5 million in a Series D round, up from a previously reported $6 million. The round is intended to back PMA approval of its Cartiva Synthetic Cartilage Implant, which it submitted to FDA last month. More

> CeQur has disclosed data that show its PaQ Insulin Delivery Device from multiple daily insulin injections can help overcome patient barriers for insulin therapy. More

Biotech News

@FierceBiotech: ICYMI Friday: EuroBiotech Report: $ABBV orders $30M of Galapagos' IPO, Indivior aces schizophrenia trial, $GILD inks Danish deal. More | Follow @FierceBiotech

@JohnCFierce: Hey, $GSK. Hyping a tiny, discovery-stage biotech as a quest for an HIV cure smells of desperation. News | Follow @JohnCFierce

> Amgen, Fidelity help bankroll another upstart gene-editing player with $27M A round. Story

> Celgene's R&D speed dating is starting to pay off, CEO says. Article

> Actavis keeps its Phase III promise with Molecular Partners' eye drug. More

Pharma News

@FiercePharma: Millions more in funding allocated to battle worst avian flu outbreak in U.S. history. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: Big news! FiercePharmaMarketing will now publish every Monday and Wednesday. More | Follow @CarlyHFierce

> HHS: Actavis could cost the government $6B with Namenda hard switch. Story

> Actavis delivers big Q1 sales boost, thanks to Forest, Allergan buys. Report

Animal Health News

> Millions more in funding allocated to battle worst avian influenza outbreak in U.S. history. Report

> Trupanion reports Q1 loss as marketing spend kicks into high gear. Item

> Mars Petcare forms new alliance to expand use of DNA testing in vet hospitals. More

> Aratana tops estimates as Q1 loss narrows. Article

> Zoetis CEO on cost-cutting push: 'We will be much more focused.' Story

Biotech IT News

> SFW Capital Partners closes $345M analytical tools fund. News

> Pfizer, 23andMe start building 5,000-person lupus database. More

> Agilent bolsters presence in clinical lab software sector with Cartagenia buyout. Report

> Medidata links its cloud platform to Apple's ResearchKit. Story

> Buzz: Apple plans to add 23andMe-style spit kits to ResearchKit studies. Article

Pharma Marketing News

> AdverseEvents: New generation of hep C meds bests older therapies in side-effect reports. More

> Secret doctor letter shows Amarin's true 'free speech' leanings. Article

> That Namenda hard switch Actavis wants? It could cost HHS $6B. Item

> Back-to-'Biogen' shift signals wider industry branding trend. News

> Is there a place for pharma in the emerging EHR market? More